New vitamin D analogs as potential therapeutics in melanoma

References

• Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp. Dermatol.16(7), 618–625 (2007).
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D: a millenium perspective. J. Cell. Biochem.88(2), 296–307 (2003).
   PubMed Web of Science ®Google Scholar
• White JH. Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis. J. Steroid Biochem. Mol. Biol.89–90, 239–244 (2004).
   Google Scholar
• Lehmann B. Role of the vitamin D3 pathway in healthy and diseased skin – facts, contradictions and hypotheses. Exp. Dermatol.18(2), 97–108 (2009).
   PubMed Web of Science ®Google Scholar
• Zmijewski MA, Li W, Zjawiony JK et al. Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids74(2), 218–228 (2009).
   PubMedGoogle Scholar
• Zbytek B, Janjetovic Z, Tuckey RC et al. 20-hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J. Invest. Dermatol.128(9), 2271–2280 (2008).
   PubMed Web of Science ®Google Scholar
• Ebert R, Schütze N, Adamski J, Jakob F. Vitamin D signaling is modulated on multiple levels in health and disease. Mol. Cell. Endocrinol.248(1–2), 149–159 (2006).
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N. Engl. J. Med.357(3), 266–281 (2007).
   PubMed Web of Science ®Google Scholar
• Bikle DD. Vitamin D: an ancient hormone. Exp. Dermatol.20(1), 7–13 (2011).
   PubMed Web of Science ®Google Scholar
• Bikle D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab.94(1), 26–34 (2009).
   PubMed Web of Science ®Google Scholar
• Bikle DD. Vitamin D: newly discovered actions require reconsideration of physiologic requirements. Trends Endocrinol. Metab.21(6), 375–384 (2010).
   PubMed Web of Science ®Google Scholar
• Glass D, Lens M, Swaminathan R, Spector TD, Bataille V. Pigmentation and vitamin D metabolism in Caucasians: low vitamin D serum levels in fair skin types in the UK. PLoS ONE4(8), e6477 (2009).
   PubMed Web of Science ®Google Scholar
• Grant WB. In defense of the sun: an estimate of changes in mortality rates in the United States if mean serum 25-hydroxyvitamin D levels were raised to 45 ng/ml by solar ultraviolet-B irradiance. Dermatoendocrinol.1(4), 207–214 (2009).
   PubMedGoogle Scholar
• Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer7(9), 684–700 (2007).
   PubMed Web of Science ®Google Scholar
• Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev.26(5), 662–687 (2005).
   PubMed Web of Science ®Google Scholar
• Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp. Dermatol.19(10), 860–864 (2010).
   Google Scholar
• Dummer R, Hauschild A, Jost L. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.19(Suppl. 2), ii86–ii88 (2008).
   PubMed Web of Science ®Google Scholar
• Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur. J. Cancer46(2), 270–283 (2010).
   PubMed Web of Science ®Google Scholar
• Egan KM. Vitamin D and melanoma. Ann. Epidemiol.19(7), 455–461 (2009).
   PubMed Web of Science ®Google Scholar
• Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev.84(4), 1155–1228 (2004).
   PubMed Web of Science ®Google Scholar
• Chang YM, Barrett JH, Bishop DT et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int. J. Epidemiol.38(3), 814–830 (2009).
   PubMed Web of Science ®Google Scholar
• Bataille V, de Vries E. Melanoma – part 1: epidemiology, risk factors, and prevention. BMJ337, a2249 (2008).
   Google Scholar
• Brozyna A, Zbytek B, Granese J, Carlson AJ, Ross J, Slominski A. Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma. Expert. Rev. Dermatol.2(4), 451–469 (2007).
   PubMedGoogle Scholar
• Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin. Proc.81(4), 500–507 (2006).
   PubMed Web of Science ®Google Scholar
• Newton-Bishop JA, Chang Y-M, Elliott F et al. Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case–control study in a temperate climate. Eur. J. Cancer47(5), 732–741 (2011).
   PubMedGoogle Scholar
• Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol. Aspects Med.29(6), 433–452 (2008).
   PubMed Web of Science ®Google Scholar
• Berwick M, Armstrong BK, Ben-Porat L et al. Sun exposure and mortality from melanoma. J. Natl Cancer Inst.97(3), 195–199 (2005).
   PubMed Web of Science ®Google Scholar
• Geller AC, Annas GD. Epidemiology of melanoma and nonmelanoma skin cancer. Semin. Oncol. Nursing19(1), 2–11 (2003).
   PubMedGoogle Scholar
• Gandini S, Raimondi S, Gnagnarella P, Doré J-F, Maisonneuve P, Testori A. Vitamin D and skin cancer: a meta-analysis. Eur. J. Cancer45(4), 634–641 (2009).
   PubMed Web of Science ®Google Scholar
• Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr. Rev.21(5), 457–487 (2000).
   PubMed Web of Science ®Google Scholar
• Hosoi J, Abe E, Suda T, Kuroki T. Regulation of melanin synthesis of B16 mouse melanoma cells by 1(alpha),25-dihydroxyvitamin D3 and retinoic acid. Cancer Res.45(4), 1474–1478 (1985).
   PubMed Web of Science ®Google Scholar
• Watabe H, Soma Y, Kawa Y et al. Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J. Invest. Dermatol.119(3), 583–589 (2002).
   PubMed Web of Science ®Google Scholar
• Bogh MK, Schmedes AV, Philipsen PA, Thieden E, Wulf HC. Vitamin D production after UVB exposure depends on baseline vitamin D and total cholesterol but not on skin pigmentation. J. Invest. Dermatol.130(2), 546–553 (2010).
   PubMed Web of Science ®Google Scholar
• Mansur CP, Gordon PR, Ray S, Holick MF, Gilchrest BA. Vitamin D, its precursors, and metabolites do not affect melanization of cultured human melanocytes. J. Invest. Dermatol.91(1), 16–21 (1988).
   Google Scholar
• Dixon KM, Norman AW, Sequeira VB et al. 1alpha,25(OH)-vitamin D and a nongenomic vitamin D analogue inhibit ultraviolet radiation-induced skin carcinogenesis. Cancer Prev. Res.4(9), 1485–1494 (2011).
   PubMed Web of Science ®Google Scholar
• Dixon KM, Sequeira VB, Camp AJ, Mason RS. Vitamin D-fence. Photochem. Photobiol. Sci.9(4), 564–570 (2010).
   Google Scholar
• Fedirko V, Bostick RM, Long Q et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev.19(1), 280–291 (2010).
   PubMed Web of Science ®Google Scholar
• Langberg M, Rotem C, Fenig E, Koren R, Ravid A. Vitamin D protects keratinocytes from deleterious effects of ionizing radiation. Br. J. Dermatol.160(1), 151–161 (2009).
   PubMed Web of Science ®Google Scholar
• Muller K, Schinn M, Reichrath J, Meineke V. 1alpha,25-dihydroxyvitamin D3 modulates the response of human keratinocytes to ionizing radiation exposure. Anticancer Res.26(4A), 2735–2741 (2006).
   Google Scholar
• Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med.364(26), 2517–2526 (2011).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med.364(26), 2507–2516 (2011).
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA305(22), 2327–2334 (2011).
   PubMed Web of Science ®Google Scholar
• Roukos DH. PLX4032 and melanoma: resistance, expectations and uncertainty. Expert Rev. Anticancer Ther.11(3), 325–328 (2011).
   PubMed Web of Science ®Google Scholar
• Brożyna AA, Jozwicki W, Janjetovic Z, Slominski AT. Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum. Pathol.42(5), 618–631 (2011).
   PubMedGoogle Scholar
• Reichrath J, Nurnberg B. Cutaneous vitamin D synthesis versus skin cancer development: the Janus faces of solar UV-radiation. Dermatoendocrinol.1(5), 253–261 (2009).
   PubMedGoogle Scholar
• Essa S, Denzer N, Mahlknecht U et al. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J. Steroid Biochem. Mol. Biol.121(1–2), 110–113 (2010).
   PubMedGoogle Scholar
• Mocellin S, Nitti D. Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. Cancer113(9), 2398–2407 (2008).
   PubMed Web of Science ®Google Scholar
• Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res.29(9), 3511–3536 (2009).
   PubMed Web of Science ®Google Scholar
• Randerson-Moor JA, Taylor JC, Elliott F et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case–control comparisons and a meta-analysis of published VDR data. Eur. J. Cancer45(18), 3271–3281 (2009).
   PubMed Web of Science ®Google Scholar
• Gapska P, Scott RJ, Serrano-Fernandez P et al. Vitamin D receptor variants and the malignant melanoma risk: a population-based study. Cancer Epidemiol.33(2), 103–107 (2009).
   PubMed Web of Science ®Google Scholar
• Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis28(2), 390–397 (2007).
   PubMed Web of Science ®Google Scholar
• Hutchinson PE, Osborne JE, Lear JT et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin. Cancer Res.6(2), 498–504 (2000).
   PubMed Web of Science ®Google Scholar
• Li C, Liu Z, Wang LE et al. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case–control study. Int. J. Cancer122(9), 2077–2084 (2008).
   PubMed Web of Science ®Google Scholar
• Li C, Liu Z, Zhang Z et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J. Invest. Dermatol.127(2), 276–280 (2007).
   PubMed Web of Science ®Google Scholar
• Santonocito C, Capizzi R, Concolino P et al. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br. J. Dermatol.156(2), 277–282 (2007).
   PubMed Web of Science ®Google Scholar
• Halsall JA, Osborne JE, Epstein MP, Pringle JH, Hutchinson PE. The unfavorable effect of the A allele of the vitamin D receptor promoter polymorphism A-1012G has different mechanisms related to susceptibility and outcome of malignant melanoma. Dermatoendocrinol.1(1), 54–57 (2009).
   PubMedGoogle Scholar
• Halsall JA, Osborne JE, Potter L, Pringle JH, Hutchinson PE. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br. J. Cancer91(4), 765–770 (2004).
   PubMed Web of Science ®Google Scholar
• Povey JE, Darakhshan F, Robertson K et al. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. Carcinogenesis28(5), 1087–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Field S, Newton-Bishop JA. Melanoma and vitamin D. Mol. Oncol.5(2), 197–214 (2011).
   PubMedGoogle Scholar
• Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog. Biophys. Mol. Biol.92(1), 49–59 (2006).
   PubMed Web of Science ®Google Scholar
• Janjetovic Z, Brozyna AA, Tuckey RC et al. High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Br. J. Cancer105(12), 1874–1884 (2011).
   PubMedGoogle Scholar
• Slominski AT, Kim TK, Janjetovic Z et al. 20-hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. Am. J. Physiol. Cell. Physiol.300(3), C526–C541 (2011).
   PubMed Web of Science ®Google Scholar
• Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, Seifert M. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol. Ther.6(1), 48–55 (2007).
   PubMed Web of Science ®Google Scholar
• Slominski AT, Zmijewski MA, Semak I et al. Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin. PLoS ONE4(2), e4309 (2009).
   PubMed Web of Science ®Google Scholar
• Zmijewski MA, Li W, Chen J et al. Synthesis and photochemical transformation of 3beta,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity. Steroids76(1–2), 193–203 (2011).
   PubMedGoogle Scholar
• Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology108(3), 1083–1086 (1981).
   PubMed Web of Science ®Google Scholar
• Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J. Differential biological effects of 1,25-dihydroxyvitamin D3 on melanoma cell lines in vitro. J. Steroid Biochem. Mol. Biol.89–90, 375–379 (2004).
   PubMedGoogle Scholar
• Gruber BM, Anuszewska EL. Influence of vitamin D3 metabolites on cell proliferation and cytotoxicity of adriamycin in human normal and neoplastic cells. Toxicol. In Vitro16(6), 663–667 (2002).
   PubMedGoogle Scholar
• Hansen CM, Madsen MW, Arensbak B, Skak-Nielsen T, Latini S, Binderup L. Down-regulation of laminin-binding integrins by 1 alpha,25-dihydroxyvitamin D3 in human melanoma cells in vitro. Cell Adhes. Commun.5(2), 109–120 (1998).
   PubMed Web of Science ®Google Scholar
• Evans SR, Houghton AM, Schumaker L et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J. Surg. Res.61(1), 127–133 (1996).
   PubMed Web of Science ®Google Scholar
• Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J. Lab. Clin. Med.133(2), 120–128 (1999).
   PubMedGoogle Scholar
• Pelczynska M, Switalska M, Maciejewska M, Jaroszewicz I, Kutner A, Opolski A. Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer Res.26(4A), 2701–2705 (2006).
   PubMedGoogle Scholar
• Danielsson C, Fehsel K, Polly P, Carlberg C. Differential apoptotic response of human melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ.5(11), 946–952 (1998).
   PubMed Web of Science ®Google Scholar
• Fleet JC, Desmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem. J.441(1), 61–76 (2012).
   PubMed Web of Science ®Google Scholar
• Frampton RJ, Omond SA, Eisman JA. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res.43(9), 4443–4447 (1983).
   PubMed Web of Science ®Google Scholar
• Oikawa A, Nakayasu M. Stimulation of melanogenesis in cultured melanoma cells by calciferols. FEBS Letters42(1), 32–35 (1974).
   Google Scholar
• Sertznig P, Seifert M, Tilgen W, Reichrath J. Activation of vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines. Dermatoendocrinol.1(4), 232–238 (2009).
   PubMedGoogle Scholar
• Guryev O, Carvalho RA, Usanov S, Gilep A, Estabrook RW. A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc. Natl Acad. Sci. USA100(25), 14754–14759 (2003).
   PubMed Web of Science ®Google Scholar
• Slominski A, Zjawiony J, Wortsman J et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur. J. Biochem.271(21), 4178–4188 (2004).
   PubMedGoogle Scholar
• Zmijewski MA, Li W, Zjawiony JK et al. Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem. Photobiol. Sci.7(12), 1570–1576 (2008).
   PubMedGoogle Scholar
• Kim T-K, Chen J, Li W et al. A new steroidal 5,7-diene derivative, 3[beta]-hydroxyandrosta-5,7-diene-17[beta]-carboxylic acid, shows potent anti-proliferative activity. Steroids75(3), 230–239 (2010).
   PubMedGoogle Scholar
• Slominski A, Semak I, Wortsman J et al. An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2. FEBS J.273(13), 2891–2901 (2006).
   PubMedGoogle Scholar
• Nguyen MN, Slominski A, Li W, Ng YR, Tuckey RC. Metabolism of vitamin D2 to 17,20,24-trihydroxyvitamin D2 by cytochrome p450scc (CYP11A1). Drug Metab. Dispos.37(4), 761–767 (2009).
   PubMedGoogle Scholar
• Valrance ME, Welsh J. Breast cancer cell regulation by high-dose vitamin D compounds in the absence of nuclear vitamin D receptor. J. Steroid Biochem. Mol. Biol.89–90(1–5), 221–225 (2004).
   PubMed Web of Science ®Google Scholar
• Nemere I, Garbi N, Hammerling GJ, Khanal RC. Intestinal cell calcium uptake and the targeted knockout of the 1,25D3-MARRS (membrane-associated, rapid response steroid-binding) receptor/PDIA3/Erp57. J. Biol. Chem.285(41), 31859–31866 (2010).
   PubMed Web of Science ®Google Scholar
• Slominski AT, Janjetovic Z, Fuller BE et al. Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. PLoS ONE5(3), e9907 (2010).
   PubMed Web of Science ®Google Scholar
• Mizwicki MT, Menegaz D, Yaghmaei S, Henry HL, Norman AW. A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure–function implications. J. Steroid Biochem. Mol. Biol.121(1–2), 98–105 (2010).
   Google Scholar
• Menegaz D, Mizwicki MT, Barrientos-Duran A, Chen N, Henry HL, Norman AW. Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). Mol. Endocrinol.25(8), 1289–1300 (2011).
   Google Scholar
• Bouillon R, Verlinden L, Eelen G et al. Mechanisms for the selective action of Vitamin D analogs. J. Steroid Biochem. Mol. Biol.97(1–2), 21–30 (2005).
   PubMed Web of Science ®Google Scholar
• Costa JL, Eijk PP, van de Wiel MA et al. Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down. BMC Genomics10, 499 (2009).
   PubMed Web of Science ®Google Scholar
• Bouillon R, Verstuyf A, Mathieu C et al. Vitamin D resistance. Best Pract. Res. Clin. Endocrinol. Metab.20(4), 627–645 (2006).
   Google Scholar
• Sauer B, Ruwisch L, Kleuser B. Antiapoptotic action of 1alpha,25-dihydroxyvitamin D3 in primary human melanocytes. Melanoma Res.13(4), 339–347 (2003).
   Google Scholar
• Tuohimaa P. Vitamin D and aging. J. Steroid Biochem. Mol. Biol.114(1–2), 78–84 (2009).
   PubMed Web of Science ®Google Scholar
• Nemere I, Safford SE, Rohe B, DeSouza MM, Farach-Carson MC. Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS) binding protein. J. Steroid Biochem. Mol. Biol.89–90, 281–285 (2004).
   Google Scholar
• Turano C, Gaucci E, Grillo C, Chichiarelli S. ERp57/GRP58: a protein with multiple functions. Cell. Mol. Biol. Lett.16(4), 539–563 (2011).
   PubMed Web of Science ®Google Scholar
• Tunsophon S, Nemere I. Protein kinase C isotypes in signal transduction for the 1,25D3-MARRS receptor (ERp57/PDIA3) in steroid hormone-stimulated phosphate uptake. Steroids75(4–5), 307–313 (2010).
   Google Scholar
• Wu W, Beilhartz G, Roy Y et al. Nuclear translocation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NFkappaB in differentiating NB4 leukemia cells. Exp. Cell. Res.316(7), 1101–1108 (2010).
   Google Scholar
• Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin. Chim. Acta372(1–2), 33–42 (2006).
   PubMed Web of Science ®Google Scholar
• Jones G. Vitamin D analogs. Endocrinol. Metab. Clin. North Am.39(2), 447–472, table of contents (2010).
   Google Scholar
• Greco M, Mitri MD, Chiriacò F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett.283(2), 222–229 (2009).
   PubMed Web of Science ®Google Scholar
• Agadir A, Lazzaro G, Zheng Y, Zhang X-K, Mehta R. Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis20(4), 577–582 (1999).
   PubMed Web of Science ®Google Scholar
• Haussler MR, Jurutka PW, Mizwicki M, Norman AW. Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)2 vitamin D3: genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab.25(4), 543–559 (2011).
   PubMed Web of Science ®Google Scholar
• Humeniuk-Polaczek R, Marcinkowska E. Impaired nuclear localization of vitamin D receptor in leukemia cells resistant to calcitriol-induced differentiation. J. Steroid Biochem. Mol. Biol.88(4–5), 361–366 (2004).
   Google Scholar
• Slominski A. Neuroendocrine activity of the melanocyte. Exp. Dermatol.18(9), 760–763 (2009).
   PubMed Web of Science ®Google Scholar
• Essa S, Reichrath S, Mahlknecht U, Montenarh M, Vogt T, Reichrath J. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. Anticancer Res.32(1), 383–389 (2012).
   Google Scholar
• Barroso E, Fernandez LP, Milne RL et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case–control studies. BMC Cancer8, 385 (2008).
   PubMed Web of Science ®Google Scholar